A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in fat metabolism promoted liver health reduced liver fat, inflammation and fibrotic remodeling (connective tissue scarring).
LVAD Monitoring App Recall; ADHD Drug & CVD Risk; Value of ATTR Treatments?
The FDA announced the class I recall of an Abbott app used to monitor patients using the HeartMate 3 Left Ventricular Assist Device (LVAD), as
March 13, 2024